Navigation Links
VIVUS to Present at the Needham and Company Life Sciences Conference
Date:6/3/2009

MOUNTAIN VIEW, Calif., June 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Dr. Barbara Troupin, senior director clinical development, will present an overview of the company at the 8th Annual Needham Life Sciences Conference.

The VIVUS presentation will take place at the New York Palace Hotel on Thursday, June 11, 2009 at 3:30 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/needham31/vvus/ or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200
                               Media Relations:     Pure Communications, Inc.
                                                    Sheryl Seapy
                                                    949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 23, 2017 ... Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), ... End User (Pharmaceutical & Biotech Companies, CRO) - Global ... the global Humanized Mouse Model Market for the forecast ... to reach USD 116.0 Million by 2021 from USD ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... entered into an underwriting agreement with Rodman & Renshaw, ... LLC, as sole book running manager and representative of several ... on a firm commitment basis a minimum of 2,105,264 ... warrants to purchase a minimum of 1,052,632 shares of ...
(Date:1/23/2017)... N.J. , Jan. 23, 2017   Enteris ... feasibility study agreement with Sanofi to leverage ... delivery platform, Peptelligence™, to develop an oral formulation of ... Joel Tune , Chief Executive Officer and Executive ... is further validation of the tremendous value our Peptelligence ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. Dr. Thomas earned ... , Dr. Thomas’ career as an academic and industry preclinical drug developer ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):